News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Launch of 20 new medicines expected by 2030
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
More than 10,000 scientific publications containing EUDRAGIT
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Launches collaborative centre for translational research in head and neck cancer
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Subscribe To Our Newsletter & Stay Updated
